FORA Capital LLC Acquires New Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

FORA Capital LLC bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, HoldingsChannel reports. The institutional investor bought 76,586 shares of the company’s stock, valued at approximately $1,411,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC boosted its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Hims & Hers Health by 3.0% in the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after buying an additional 1,173 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 1.1 %

Shares of Hims & Hers Health stock opened at $30.35 on Thursday. The stock’s 50-day simple moving average is $21.14 and its 200-day simple moving average is $19.57. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $35.02. The company has a market capitalization of $6.63 billion, a price-to-earnings ratio of 68.98 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period in the previous year, the business earned ($0.04) earnings per share. The business’s revenue was up 77.1% on a year-over-year basis. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.60, for a total value of $169,491.40. Following the sale, the chief financial officer now directly owns 181,469 shares of the company’s stock, valued at approximately $2,649,447.40. The trade was a 6.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $487,789.12. This trade represents a 84.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,153,519 shares of company stock valued at $24,486,721. 17.71% of the stock is currently owned by insiders.

Analyst Ratings Changes

HIMS has been the topic of a number of research reports. Piper Sandler restated a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Finally, Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.71.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.